MetaCap

Starling Oncology Inc. (STLN)

NASDAQ: STLNHealth CareMedical/Nursing ServicesUSD

3.00-0.18 (-5.66%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

STLN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$305.97M
EPS (TTM)
-$0.28
52-week range
2.32 – 7.13
Day range
2.97 – 3.27
Volume / Avg
5.86M / 2.55M
Beta
—

52-week range

$2.32$7.13

STLN stock today

On Nov 20, STLN ended the session at $3.00, shedding $0.18 (5.66%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 5.86M shares, a sign of unusually heavy trading. Shares are 57.9% below their 52-week high of $7.13, set on Sep 18, 2026 and 29.3% above the 52-week low of $2.32, near the bottom of the past year's range.

STLN is down 15.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.2%. Starling Oncology has posted a net loss over the last twelve months (EPS of -$0.28), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Starling Oncology

Company profile

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services.

Industry
Medical/Nursing Services
CEO
Dr. Daniel Virnich FACHE, M.B.A., M.D.
Headquarters
Cerritos, CA
Employees
641
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Starling Oncology generated $502.7 million in revenue, up 27.8% from fiscal 2024, its 5th consecutive year of revenue growth. Starling Oncology reported a net loss of $60.6 million, compared with a loss of $64.7 million a year earlier. Operating margin was -7.2%.

Starling Oncology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$502.73M$393.41M$324.24M$252.48M$203.00M
Growth+27.79%+21.33%+28.42%+24.37%+8.26%
Net income$-60.61M$-64.66M$-83.07M$152.00K$-10.93M
EPS (diluted)$-0.54$-0.71$-0.92$-0.21$-0.16

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$9.25+208.33%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.14 vs $-0.07
Surprise
-100.00%

STLN news

All STLN news

Starling Oncology peers

Health Care sector
STLN peer companies
CompanyPrice% ChgMarket capCompare
AUNAAuna SA Class A3.66-6.15%$271.05Mvs STLN
PIIIP3 Health Partners Inc. Class A1.69-9.14%$350.24Mvs STLN
SRTAStrata Critical Medical Inc. Class A4.56-5.59%$407.30Mvs STLN
SBCSBC Medical Group Holdings Incorporated5.17-7.68%$530.32Mvs STLN
LFMDLifeMD Inc.1.45-9.40%$69.84Mvs STLN
NAKANakamoto Inc.3.44-15.89%$63.11Mvs STLN
EUDAEUDA Health Holdings Limited Class A15.96-7.69%$47.79Mvs STLN
AIRSAirSculpt Technologies Inc.0.5907-9.72%$43.67Mvs STLN

Indexes, lists and sector

Starling Oncology stock FAQ

What is Starling Oncology's stock price today?

STLN last traded at $3.00 as of Nov 20, 4:00 PM EST, down 5.66% on the day. Prices are delayed at least 15 minutes.

Who is Starling Oncology's CEO?

Dr. Daniel Virnich FACHE, M.B.A., M.D. is the chief executive officer of Starling Oncology Inc., which has about 641 employees.

What is the STLN 52-week high?

The 52-week high for STLN is $7.13 and the 52-week low is $2.32. The stock is currently 57.9% below its high.

Compare STLN